Spinal-Epidural Analgesia for Labor Pain
Trial Summary
What is the purpose of this trial?
Combined spinal-epidural (CSE) for labor analgesia has been used for many years and is practiced commonly at our institution, especially when the patient requests immediate pain relief. CSE is not only beneficial for its faster onset of analgesia, but also it is favorable in relation to the need for rescue analgesia, urinary retention, and rate of instrumental delivery compared to the traditional epidural. Despite its beneficial effects, there is a risk of about 15-30% of developing abnormal fetal heart rate following CSE. This is self-resolving with minimal or no intervention. Although the cause of fetal bradycardia is not fully elucidated, variations in uterine artery blood flow after epidural analgesia are thought to be due to the interaction of numerous events related to blockade of sympathetic innervations, fluid administration, maternal hypotension, uterine vascular effects of sympathetic block, fluctuations in circulating catecholamines, and possibly the effect of opioids. Similar mechanism is thought to be a cause of fetal bradycardia after the CSE with its faster onset and superior block. Maternal or fetal circulation during labor can be assessed using continuous-wave Doppler ultrasound to monitor maternal uterine artery (UtA) and fetal umbilical artery (UmA) velocity waveforms to detect changes in blood flow. The velocimetry indices mentioned above have been often used to assess the changes in the blood flow before and after the induction of epidural analgesia during labor in several studies. Although there are some studies regarding the effect of labor epidural analgesia using velocimetry indices, but there is currently no published study evaluating velocimetry indices of uterine and umbilical arteries before and after the induction of CSE. Thus, the aim of this study is to investigate the impact of CSE to maternal and fetal blood flow to evaluate the relationships. The investigators hypothesize that both uterine artery and umbilical artery blood flow are reduced after the induction of CSE, which may be responsible for the occurrence of fetal bradycardia.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Combined Spinal-epidural Analgesia for labor pain?
Is combined spinal-epidural analgesia safe for labor pain management?
How does the treatment Combined Spinal-Epidural Analgesia (CSE) differ from other treatments for labor pain?
Combined Spinal-Epidural Analgesia (CSE) is unique because it combines the rapid onset and reliable pain relief of spinal anesthesia with the ability to adjust and prolong pain relief through continuous epidural anesthesia. This approach allows for fast pain relief and the option for the mother to walk during labor, known as a 'walking epidural', which is not typically possible with traditional epidural alone.12489
Research Team
Mrinalini Balki, MD
Principal Investigator
MOUNT SINAI HOSPITAL
Eligibility Criteria
This trial is for laboring women experiencing pain during childbirth. It's not specified who can't participate, but typically those with certain medical conditions or risks might be excluded.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Baseline velocimetric indices and pain scores are measured prior to combined spinal epidural
Treatment
Participants receive combined spinal-epidural analgesia, and velocimetric indices are measured at various intervals
Follow-up
Participants are monitored for safety and effectiveness after treatment, including fetal heart rate and maternal blood pressure
Treatment Details
Interventions
- Combined Spinal-epidural Analgesia (Procedure)
Combined Spinal-epidural Analgesia is already approved in Canada for the following indications:
- Labour pain relief
- Obstetric analgesia
Find a Clinic Near You
Who Is Running the Clinical Trial?
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Lead Sponsor
Dr. Anne-Claude Gingras
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Chief Executive Officer
PhD in Functional Proteomics, Canada Research Chair
Dr. Susanna Mak
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Chief Medical Officer since 2004
MD, University of Toronto